Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STADIA-HFpEF dapagliflozin crossover study in early HFpEF
NL-OMON49053Phase 2Recruiting
- Sponsor
- OLVG
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by OLVG. Primary endpoints: Change in echocardiographic E/E'/LVEDV and Change in mean LV E'. Started Sep 2020; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON49053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49053.